AKT1 and renal cell carcinoma: Morphoproteomic analysis of biopsies from RCC patients who clinically progress despite temsirolimus or everolimus therapy has revealed constitutively activated STAT3 and ERK pathways in collaboration with the mTOR complex 2 (mTORC2) and Akt [17].